Strength training participants who experienced greater clinical benefit saw a decrease in CDKN1A expression (Figure 5D), suggesting a potential beneficial relationship between decreased CDKN1A expression and clinical outcomes for patients with DM1. This evidence concerns the gene CDKN1A and myotonic dystrophy type 1.